Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

Links shared publicly online about this topic.

253
total visits

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

View full resource at news-medical.net

Tags: Heart, Sexual Health, Cancer, Breast Cancer, Pharma, Women's Health, Safety